Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
The Captial Market (CapitalMarket.com) rating for Innova Captab IPO is 44. Their analysis recommends Avoid, However active risk seekers can try for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 44 | Avoid, However active risk seekers can try |
[Dilip Davda] The company is a branded generic pharmaceutical products manufacturer for the domestic and international markets. It has posted growth in its top and bottom lines. Recent acquisition of Sharon Bio by the company augurs well for its synergistic growth plans. It is also gearing for new product portfolio with its upcoming new plant at Jammu. Based on FY24 annualized earnings, the issue appears fully priced, but it is poised for bright prospects post expansion. Investors may park funds for the medium to long term rewards. Read detail review...
Innova Captab Limited peer comparison with similar listed entities. (As on March 31, 2023)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | Closing price as on period ended | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|---|
| Innova Captab Limited | 14.16 | 14.16 | 57.60 | 24.58 | Consolidated | |||
| Torrent Pharmaceuticals Limited | 36.79 | 36.79 | 182.97 | 57.61 | 20.11 | 2,119.65 | 11.58 | Consolidated |
| Laurus Labs Limited | 14.69 | 14.64 | 74.92 | 25.53 | 19.74 | 373.70 | 4.99 | Consolidated |
| Ajanta Pharma Limited | 45.89 | 45.89 | 267.41 | 42.91 | 17.36 | 1,969.15 | 7.36 | Consolidated |
| J. B. Chemicals and Pharmaceuticals Limited | 53.00 | 52.34 | 320.36 | 28.61 | 16.54 | 1,497.30 | 4.67 | Consolidated |
| NATCO Pharma Limited | 39.18 | 39.18 | 264.21 | 19.90 | 14.84 | 779.55 | 2.95 | Consolidated |
| Eris Lifesciences Limited | 28.10 | 28.07 | 160.85 | 33.01 | 17.10 | 926.70 | 5.76 | Consolidated |
| Indoco Remedies Limited | 15.44 | 15.42 | 111.58 | 22.74 | 13.83 | 350.70 | 3.14 | Consolidated |
| Suven Pharmaceuticals Limited | 16.16 | 16.16 | 68.16 | 37.13 | 23.70 | 600.05 | 8.80 | Consolidated |
| Windlas Biotech Limited | 19.70 | 19.70 | 192.02 | 22.04 | 10.61 | 434.25 | 2.26 | Consolidated |
Note:
All the financial information for listed industry peers mentioned above is on a consolidated basis and is sourced from the annual reports as available of the respective company for the year ended March 31, 2023. The information for Innova Captab Limited has been sourced from the Restated Consolidated Financial Information for the year ended March 31, 2023.
The financial parameters above are not reclassified by CRISIL and taken as reported by players.
Closing Price has been taken as of November 21, 2023
Hence, the comparison should not be made with the tables in the rest of the competitive section of the "Industry Overview" section.
The financial parameters are calculated as described below:
Net worth = Equity share capital + Other equity-capital reserves
NAV per share = Net worth / Number of equity shares outstanding R
eturn on net worth = PAT / Net worth
Innova Captab IPO Reviews, analysis and views by popular members. Read Innova Captab Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP